An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease

Mathews, Sony; Reid, Ashley; Tian, Chenlu; Cai, Qiang

doi:10.2147/ceg.s6355

Cited by 13 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unlike other PPIs, the serum concentration of pantoprazole is not dose-dependent; serum concentration after the first dose is similar to that following multiple doses. The metabolism of pantoprazole is independent of route of administration, with a half-life of approximately 1 hour [ 22 ]. Gastric acid suppression is a class effect of the PPIs.…”

Section: Discussionmentioning

confidence: 99%

Effect of morning versus night-time administration of proton pump inhibitor (pantoprazole) on thyroid function test in levothyroxine-treated primary hypothyroidism: a prospective cross-over study

et al. 2023

View full text Add to dashboard Cite

Background One of the common causes of suboptimal control of thyroid stimulating hormone (TSH) in levothyroxine-treated hypothyroidism is coadministration of proton pump inhibitors (PPIs). Morning administration of pantoprazole has been shown to suppress intragastric pH to a greater extent. We therefore aimed to determine the effect of pantoprazole at different time points of the day on thyroid function test (TFT) in levothyroxine-treated overt primary hypothyroidism. Methods In this single centre, hospital based, prospective, two arm cross-over study (AB, BA), participants were randomized into 2 groups based on morning (6:00 am – 7:00 am simultaneously with the scheduled levothyroxine tablet) (group M) and evening (30 min before dinner) intake of 40 mg pantoprazole tablet (group N). After the initial 6 weeks (period 1), a washout period of 1 week for pantoprazole was given, and then both the groups crossed over for another 6 weeks (period 2). Patients were instructed to continue the same brand of levothyroxine tablet at empty stomach 1-hour before breakfast. Serum TSH was measured at baseline, week 6, and week 13. Results Data from 30 patients, who completed the study with 100% compliance, were analysed. Mean TSH values of the study participants were significantly higher both at week 6 and week 13 compared to the baseline. Mean baseline serum TSH concentrations for groups M and N were 2.70 (± 1.36), and 2.20 (± 1.06) µlU/mL, respectively. Mean serum TSH concentrations at the end periods 1 and 2 for group M were 3.78 (± 4.29), and 3.76 (± 2.77) while the levels in group N were 3.30 (± 1.90), and 4.53 (± 4.590) µlU/mL, respectively. There was a significant rise in serum TSH concentration across periods 1 and 2 in both the groups (F2, 58 = 3.87, p = 0.03). Within group changes in TSH across periods 1 and 2 were not statistically significant. Similarly difference in TSH between the groups, either at 6 weeks or at 13 weeks, were also not statistically significant. Conclusions Concomitant use of pantoprazole, even for 6 weeks, leads to significant elevation in serum TSH in levothyroxine-treated patients who are biochemically euthyroid, irrespective of timing of pantoprazole intake. Early morning and night-time administration of pantoprazole have similar effect on TFT in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of morning versus night-time administration of proton pump inhibitor (pantoprazole) on thyroid function test in levothyroxine-treated primary hypothyroidism: a prospective cross-over study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Pantoprazole was chosen as the reference PPI for comparison in the study as it does not possess CYP2C19 inhibitory potency, lacks the potential for drug-drug interactions with clopidogrel, and has been recommended by Food and Drug Administration as a PPI of choice in clopidogrel-treated patients. 30,31…”

Section: Pantoprazole Vs Other Ppis In Increased Cardiovascular Riskmentioning

confidence: 99%

Prevalence and Safety of Prescribing PPIs with Clopidogrel in Palestine

Abukhalil¹,

Sheikh²,

Muallem³

et al. 2023

PPA

View full text Add to dashboard Cite

Background: Proton pump inhibitors (PPIs) are commonly prescribed medications that are thought to increase the risk of cardiovascular events because they reduce the effectiveness of clopidogrel via shared hepatic pathways. Objective: This study examined the prevalence of concomitant prescribing of clopidogrel/PPI among patients diagnosed with acute coronary syndrome and the adverse cardiovascular event associated with this interaction. Methods: A retrospective cohort study was conducted by retrieving patient data from the Nat Health Insurance claims processor database in Palestine. Adults diagnosed with Acute Coronary Syndrome (ACS) from 2019 through 2021 who were prescribed clopidogrel or clopidogrel in combination with a PPI were included in the study. Endpoints were adverse cardiac events, including readmission for revascularization during the first year of treatment. Results:The study included 443 patients; the prevalence of prescribing concomitant clopidogrel with a PPI was 74.7%, whereas 49.2% were prescribed interacting PPI (omeprazole, esomeprazole, and lansoprazole). 59 (13.3%) of participants experienced a cardiovascular event within 1 year of starting therapy, including 27 (12.4%) patients who had a cardiovascular event while taking an interacting PPI. No significant association was found between PPI administration and increased CV event risk in patients receiving concomitant clopidogrel and PPIs therapy (p = 0.579). Conclusion:In this study, we observed a high prevalence of prescribing a PPI in combination with clopidogrel, regardless of the FDA recommendations. No significant increase in cardiovascular events was observed in patients receiving concomitant clopidogrel and PPI therapy.

show abstract

“…Пантопразол был одобрен FDA (Food and Drug Administration, Управление США по санитарному надзору за качеством пищевых продуктов и медикаментов) для лечения эрозивного эзофагита как формы ГЭРБ в 2000 г. [7]. За прошедшие годы были проведены исследования, подтвердившие высокую эффективность пантопразола при лечении ГЭРБ.…”

Section: применение пантопразола при гастроэзофагеальной рефлюксной б...unclassified

Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases

Шептулин

Кардашева

Курбатова

2021

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

Aim. An outline of the current potential of pantoprazole in treatment and prevention of upper gastrointestinal diseases.Key points. Pantoprazole is widely applied in gastroesophageal reflux, peptic ulcer disease, Zollinger—Ellison syndrome and for Helicobacter pylori eradication. It minimally inhibits the CYP2C19 isoenzyme involved in the metabolism of many drugs. Pharmacokinetics of pantoprazole conditions a weaker drug interaction compared to other proton pump inhibitors (PPIs), which enables its use for gastrointestinal bleeding prevention in patients receiving dual antiplatelet therapy. The new coronaviral pandemic of COVID-19 urges the selection of PPIs that minimise the drug interference, such as pantoprazole, in therapy and prevention of acid-related upper gastrointestinal diseases. Pantoprazole has a good tolerance and low side effect rate.Conclusion. Pantoprazole is considered among optimal PPIs for efficacy, safety and adherence on the basis of clinical trials for treatment and prevention of gastrointestinal diseases, systematic reviews and meta-analyses.

show abstract

An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease

Cited by 13 publications

References 59 publications

Effect of morning versus night-time administration of proton pump inhibitor (pantoprazole) on thyroid function test in levothyroxine-treated primary hypothyroidism: a prospective cross-over study

Effect of morning versus night-time administration of proton pump inhibitor (pantoprazole) on thyroid function test in levothyroxine-treated primary hypothyroidism: a prospective cross-over study

Prevalence and Safety of Prescribing PPIs with Clopidogrel in Palestine

Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases

Contact Info

Product

Resources

About